Supernus hits Zydus with repeat suit over migraine drug

Supernus Pharmaceuticals has once again accused Indian generic drugmaker Zydus Cadila and its US unit of allegedly infringing 10 patents with its copycat of Trokendi XR (topiramate), a drug for migraines and seizures.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Endo sues Indian drug maker over anti-smoking drug patent

10 August 2023 Patent-in-suit relates to a synthetic drug used to treat nicotine dependence | Development comes after USFood and Drug Administration sets new guidelines forcing the withdrawal of another big pharma firm’s rival drug.

Big Pharma

Zydus challenges ruling in Takeda antitrust dispute

16 June 2022 Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.

Americas

Fed Circuit opens door for additional pharma revenues in Supernus decision

24 January 2019 The US Court of Appeals for the Federal Circuit has overturned a reduction in the patent term adjustment owned by Supernus Pharmaceuticals.

More features

How 'Boehringer' sets preliminary relief threshold for generics

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Supernus hits Zydus with repeat suit over migraine drug

More on this story

Editor's picks

Editor's picks

More features